Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 49: 248-252, 2003; 10.1373/49.2.248
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (18)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sandri, M. T.
Right arrow Articles by Cipolla, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sandri, M. T.
Right arrow Articles by Cipolla, C. M.
Related Collections
Right arrow Evidence Based Laboratory Medicine and Test Utilization
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2003;49:248-252.)
© 2003 American Association for Clinical Chemistry, Inc.

Minor Increases in Plasma Troponin I Predict Decreased Left Ventricular Ejection Fraction after High-Dose Chemotherapy

Maria Teresa Sandri1a, Daniela Cardinale2, Laura Zorzino1, Rita Passerini1, Paola Lentati1, Alessandro Martinoni2, Giovanni Martinelli3 and Carlo Maria Cipolla2

1 Division of Pathology, Laboratory Medicine Unit,
2 Cardiology Unit, and
3 Division of Hematoncology, European Institute of Oncology, via Ripamonti 435, 20141 Milan, Italy.

aAuthor for correspondence. Fax 39-02-57489417; e-mail maria.sandri{at}ieo.it.

Background: Increased cardiac troponin I (cTnI) in patients treated with high-dose chemotherapy (HDCT) for aggressive malignancy has been proposed as an early marker of late HDCT-induced cardiac dysfunction. We investigated whether cTnI measured by the Stratus CS (Dade Behring) would allow detection of minimal cTnI increases in patients treated with HDCT.

Methods: Plasma cTnI concentrations were determined in 179 consecutive patients before HDCT, at the end of the treatment, and after 12, 24, 36, and 72 h. Cardiac function was explored by echocardiography, and left ventricular ejection fraction (LVEF) was recorded during follow-up. The greatest variation in LVEF from the baseline value was used as a measure of cardiac damage.

Results: In 99 healthy volunteers, the 99th percentile was at 0.07 µg/L. On the basis of ROC curve analysis (area under the curve, 0.89), a cutoff of 0.08 µg/L was chosen (sensitivity, 82%; specificity, 77%). cTnI >=0.08 µg/L occurred in 57 patients (32%) with echocardiographic monitoring revealing a mean decrease in LVEF of 18%. In comparison, the group of cTnI-negative patients had a mean decrease in LVEF of 2.5% (P <0.001).

Conclusions: Plasma cTnI, as measured with the Stratus CS, can detect minor myocardial injury in patients treated with HDCT.




The following articles in journals at HighWire Press have cited this article:


Home page
 CirculationHome page
D. Cardinale, A. Colombo, M. T. Sandri, G. Lamantia, N. Colombo, M. Civelli, G. Martinelli, F. Veglia, C. Fiorentini, and C. M. Cipolla
Prevention of High-Dose Chemotherapy-Induced Cardiotoxicity in High-Risk Patients by Angiotensin-Converting Enzyme Inhibition
Circulation, December 5, 2006; 114(23): 2474 - 2481.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
M. T. Sandri, M. Salvatici, D. Cardinale, L. Zorzino, R. Passerini, P. Lentati, M. Leon, M. Civelli, G. Martinelli, and C. M. Cipolla
N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?
Clin. Chem., August 1, 2005; 51(8): 1405 - 1410.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
D. Cardinale, M. T. Sandri, A. Colombo, N. Colombo, M. Boeri, G. Lamantia, M. Civelli, F. Peccatori, G. Martinelli, C. Fiorentini, et al.
Prognostic Value of Troponin I in Cardiac Risk Stratification of Cancer Patients Undergoing High-Dose Chemotherapy
Circulation, June 8, 2004; 109(22): 2749 - 2754.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
I. Oztop, M. Gencer, T. Okan, A. Yaren, E. Altekin, S. Turker, and U. Yilmaz
Evaluation of Cardiotoxicity of a Combined Bolus plus Infusional 5-Fluorouracil/Folinic Acid Treatment by Echocardiography, Plasma Troponin I Level, QT Interval and Dispersion in Patients with Gastrointestinal System Cancers
Jpn. J. Clin. Oncol., May 1, 2004; 34(5): 262 - 268.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the American Association for Clinical Chemistry.